Skip to main content
Premium Trial:

Request an Annual Quote

BioMark Diagnostics Raises C$1.5M to Commercialize Lung Cancer Liquid Biopsy Test

NEW YORK – Liquid biopsy firm BioMark Diagnostics said Wednesday that it has raised C$1.5 million (US$1.2 million) through a private financing round and new line of credit to help accelerate the commercialization of its lung cancer detection technology.

In a private placement, BioMark issued 5,062,000 units — consisting of one common share of its stock and one full purchase warrant — at a price of C$.25 per unit for gross proceeds of approximately C$1.3 million.

The company said the issued securities will be subject to a hold period of four months and one day. Each purchase warrant entitles its holder to purchase one common share of BioMark at $.45 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause.

In addition, the company secured a non-dilutive line of credit up to C$235,000 through its Quebec City-based, wholly owned subsidiary BioMark Diagnostic Solutions.

The firm intends to use the C$1.5 million to seek lab accreditation, perform an assay validation and verification study, participate in a large-scale lung cancer screening program in Quebec, and perform business development activities in the US.

BioMark President and CEO Rashid Bux said in a statement that the company plans to commercialize its early lung cancer test within 12 to 18 months.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.